Search

Displaying results 8381 - 8390 of 8545 in total
  1. Drug

    Pralnacasan

    go.drugbank.com/drugs/DB04875
    Experimental

    Pralnacasan is an orally bioavailable pro-drug of a potent, non-peptide inhibitor of interleukin-1beta converting enzyme (ICE).

  2. Drug

    Sovateltide

    go.drugbank.com/drugs/DB06138
    Investigational

    It is being developed as an adjunct to chemotherapy.

  3. Drug

    SUVN-502

    go.drugbank.com/drugs/DB06140
    Investigational

    SUVN-502 is a novel, potent, safe, highly selective and orally active antagonist at a central nervous system serotonin receptor site 5-HT6 intended for treatment of cognitive disorders such as Alzheimer

  4. Drug

    Isatin

    go.drugbank.com/drugs/DB02095
    Experimental

    Isatin is an indole derivative first obtained by Erdman and Laurent in 1841 as an oxidation product of Indigo dye with nitric acid and chromic acids.

  5. Drug

    Ammonium molybdate

    go.drugbank.com/drugs/DB11128
    Investigational

    It is intravenously administered as an additive to solutions for Total Parenteral Nutrition (TPN).

    Synonyms: Molybdenum (as ammonium molybdate)
  6. Drug

    Bardoxolone methyl

    go.drugbank.com/drugs/DB05983
    Investigational

  7. Drug

    INO-4800

    go.drugbank.com/drugs/DB15693
    Investigational

    (NCT04336410) was started on April 3, 2020, with an expected completion date of July 2021. … [L14372] A Phase 1/2 clinical trial through South Korea's Seoul National University Hospital was announced on June 4, 2020, and expected to start later in the month.[L14375]

  8. Drug

    LY2275796

    go.drugbank.com/drugs/DB05165
    Investigational

    LY2275796 is a second-generation antisense anti-cancer drug candidate for clinical development. LY2275796 targets eukaryotic initiation factor- 4E (eIF-4E), a protein involved in the translation of key growth and survival factors that dr...

  9. Drug

    Tosatoxumab

    go.drugbank.com/drugs/DB16557
    Investigational

    Tosatoxumab is a fully-human monoclonal antibody (IgG1λ) targeting the Staphylococcus aureus alpha-toxin or the S. aureus alpha-hemolysin and thereby preserving human immune cells by protecting against destruction of host cells mediated ...

  10. Drug

    Talacotuzumab

    go.drugbank.com/drugs/DB14796
    Investigational

    Talacotuzumab is an IgG1 monoclonal antibody directed toward the IL3 receptor α–subunit, also known as CD123.